Your session is about to expire
← Back to Search
Pembrolizumab + Vorinostat for Lymphoma
Study Summary
This trial is testing vorinostat + pembrolizumab to see if it's more effective than pembrolizumab alone in treating patients with DLBCL, FL, or HL.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this research project still in the recruitment phase?
"As displayed on clinicaltrials.gov, the recruitment for this medical trial has been suspended since June 8th 2022; it was initially posted in July 2017. Although enrollment is closed currently, there are 3680 other studies that are actively accepting participants."
Are there any other experiments that have made use of Vorinostat?
"As of today, 986 clinical trials centered around Vorinostat are taking place with 124 Phase 3 trails specifically. Across 36506 sites located both locally and world-wide, Sacramento has one of the highest concentrations for this drug's research."
What are the risks associated with Vorinostat administration?
"Our analysts at Power have scored the safety of Vorinostat with a 1 due to this being an early-stage trial, suggesting that there is currently limited evidence supporting its efficacy and security."
What type of medical condition is Vorinostat usually administered to address?
"Malignant neoplasms are often managed with Vorinostat, but its therapeutic effects can extend to those suffering from progressive cutaneous T-cell lymphoma, microsatellite instability high, and unresectable melanoma."
How many participants are being recruited for this clinical research study?
"Unfortuntely, this research study has ceased to accept new enrollees. The initial posting date was July 18th 2017 and it was last updated on June 8th 2022. For others searching for clinical trials related to b-lymphocytes, there are 2694 studies that remain recruiting patients; alternatively, 986 medical investigations pertaining to Vorinostat have open slots available too."
Share this study with friends
Copy Link
Messenger